Phase 1b Data for Topical Pravibismane in Diabetic Foot Ulcer Infection Demonstrates Favorable Effects and Safety
Summary: Dermatology Times reports Phase 1b results for topical pravibismane used adjunctively in moderate to severe infected diabetic foot ulcers. The therapy was well-tolerated and associated with favorable healing signals alongside standard care, with the source article published in the International Wound Journal.
Key Highlights:
- Adjunct topical pravibismane vs placebo in infected DFUs.
- Safety and tolerability demonstrated across tested doses.
- Signals toward greater ulcer-size reduction and fewer ulcer-related amputations.
- Larger, confirmatory trials are warranted.
Keywords: pravibismane, diabetic foot ulcer, International Wound Journal, Lipsky